The Department of Energy’s National Nuclear Security Administration has issued a cooperative agreement worth $35 million to SHINE Technologies, based in Janesville, Wis., to support the commercial production of molybdenum-99, a critical isotope used in more than 40,000 medical procedures in the United States each day, including the diagnosis of heart disease and cancer.

ARTMS, a Canadian producer of medical isotopes, announced that it has registered the cyclotron production of gallium-68 with the government of Canada, filing a Type 1 Master File with the Health Products & Food Branch of Health Canada. The Ga-68 radioisotope is used in nuclear medicine diagnostic procedures utilizing positron emission tomography (PET) imaging.

NorthStar Medical Technologies of Beloit, Wis., will receive $37 million under two cooperative agreements with the National Nuclear Security Administration for the production of molybdenum-99 without the use of high-enriched uranium. Considered a critical medical radioisotope, Mo-99 is used in more than 40,000 medical procedures in the United States each day, including the diagnosis of heart disease and cancer.

Key facilities at a multipurpose nuclear research center in the high plains of Bolivia are nearing operation, and a ceremonial first concrete pour for the nuclear research reactor that will serve as the centerpiece of the project was held on July 26. Bolivian president Luis Arce attended the ceremony at the Center for Nuclear Technology Research and Development (CNTRD). Also attending were Kirill Komarov, first deputy director general for corporate development and international business at Rosatom (Russia’s state atomic energy agency), and authorities from the Ministry of Hydrocarbons and Energies and the Bolivian Nuclear Energy Agency (ABEN).

SHINE Medical Technologies plans to locate its European medical isotope production facility in the Netherlands after a yearlong search and a review of more than 50 proposals from sites across Europe. The company announced on May 20 that construction at the site should begin in 2023 with commercial production starting in late 2025.

Darlington nuclear generating station. Photo: OPG

Ontario Power Generation, its subsidiary Laurentis Energy Partners, and BWXT ITG Canada and its affiliates announced on September 24 that the companies are making “significant progress” toward the production of molybdenum-99 at OPG’s Darlington nuclear power plant. Darlington will become the first commercial operating nuclear reactor to produce the medical radioisotope.

A precursor to technetium-99m, Mo-99 is used in more than 40 million procedures a year to detect cancers and diagnose various medical conditions.

An Atlas V rocket with NASA’s Mars 2020 Perseverance rover on board launches on July 30. Photo: NASA/Joel Kowsky

The launch of the Mars 2020 Perseverance rover went ahead as scheduled on July 30, lifting off from Space Launch Complex 41 at Cape Canaveral Air Force Station in Florida at 7:50 a.m. (EDT) . The rover was onboard a United Launch Alliance Atlas V 541 rocket.

Minutes later, NASA reported that all flight milestones were being met as planned. There are several more milestones to reach before Perseverance—the fifth rover that NASA has sent to Mars—lands on the Red Planet in seven months.

The International Atomic Energy Agency has emphasized that elevated concentrations of cesium-134, cesium-137, and ruthenium-103 recently detected over Northern Europe pose no risk to human health or the environment, even as the agency continues to investigate their origin.